Skip to content
Research Article Open access CC BY 4.0

Can Glycosylated Hemoglobin and C-reactive Protein Levels Predict Development of Subclinical Neuropathy in Pre-diabetics?

Ahmed Esmael, Mohammad Abu-Hegazy, Amr Elrabat

International Neuropsychiatric Disease Journal · pp. 1–8 · Published 4 Dec 2015

10.9734/INDJ/2016/22316

Abstract

Background: Individuals with elevated glycosylated hemoglobin (HbA1c) have a higher rate of microvascular complications, especially peripheral neuropathy. Objective: To  find the relation  between  elevated   (HbA1c) and the  occurrence of  peripheral  nerve dysfunction in prediabetic individuals and to find  the role of the  inflammatory marker as,  C-Reactive  Protein (CRP),  in  the  development  of  Diabetic Peripheral Neuropathy (DPN). Methods: Screening was done for 80 pre-diabetic individuals and 40 control subjects presenting to the internal medicine clinics,  Mansoura University Hospital; Egypt, from August 2014 to July 2015. The pre-diabetic individuals (HBA1c: 6.0-6.5%)   and a control group of 40 subjects with HbA1c < 6%. All subjects underwent neurological examination, nerve conduction study of both peroneal and sural nerves, and measurement of HbA1c and CRP. Results: The sural nerve Sensory Nerve Action Potential (SNAP) amplitude was significantly lower in pre-diabetics than in control group. Compound Muscle Action Potential (CMAP) of the peroneal nerve was lower significantly in pre-diabetics with subclinical neuropathy in comparison to controls. The peroneal and sural nerve amplitudes were significantly correlated to CRP, but not to HbA1c. Conclusion: Axonal subclinical neuropathy occurs significantly more in pre-diabetics than in normal (control) individuals. The CRP is significantly correlated with the presence of the axonal subclinical neuropathy which indicates an underlying inflammatory role.  

Subclinical neuropathy prediabetic inflammatory markers glycosylated hemoglobin

References (28)

  1. 1 Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications [DOI]
  2. 2 Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. [DOI]
  3. 3 Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy [DOI]
  4. 4 Diabetic neuropathy—a review [DOI]
  5. 5 Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease [DOI]
  6. 6 Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes?the EURODIAB Prospective Complications Study [DOI]
  7. 7 Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic Neuropathy [DOI]
  8. 8 Genetic Variation, C-Reactive Protein Levels, and Incidence of Diabetes [DOI]
  9. 9 Neuropathy in prediabetes: does the clock start ticking early? [DOI]
  10. 10 Diabetic Neuropathies [DOI]
  11. 11 Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study [DOI]
  12. 12 Implications of Using Hemoglobin A1C for Diagnosing Diabetes Mellitus [DOI]
  13. 13 Endoneurial localisation of microvascular damage in human diabetic neuropathy [DOI]
  14. 14 Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus [DOI]
  15. 15 Is Inflammation a Common Retinal-Renal-Nerve Pathogenic Link in Diabetes? [DOI]
  16. 16 A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy [DOI]
  17. 17 High-Sensitivity C-Reactive Protein Levels and Type 2 Diabetes in Urban North Indians [DOI]
  18. 18 The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus [DOI]
  19. 19 A comparison of electrophysiological tests for the early diagnosis of diabetic neuropathy [DOI]
  20. 20 Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control [DOI]
  21. 21 Biologic Variability in Plasma Glucose, Hemoglobin A1c, and Advanced Glycation End Products Associated with Diabetes Complications [DOI]
  22. 22 Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea [DOI]
  23. 23 Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation? [DOI]
  24. 24 Relationship between C peptide and chronic complications in type-2 diabetes mellitus.
  25. 25 Microvascular Complications in Adolescents with Type 1 Diabetes Mellitus [DOI]
  26. 26 Subclinical neuropathy in type I diabetic children [DOI]
  27. 27 Neuropathy associated with prediabetes: What is new in 2007? [DOI]
  28. 28 The Optimal Cutoff Value of Glycated Hemoglobin for Detection of Diabetic Retinopathy [DOI]

Cited by 1

SUBCLINICAL INFLAMMATION; ANTI INFLAMMATORY EFFECT OF SITAGLIPTIN IN TYPE 2 DIABETIC DYSLIPIDEMIC PATIENTS

M. Hussain, M. B. Ghafoor, M. Hussain · 2016

Related research

Article metrics

Real usage data collected on this platform.

26

Page views

0

PDF downloads

7

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.